As per MRFR analysis, the Graves Ophthalmopathy Market Size was estimated at 1.6 (USD Billion) in 2022. The Graves Ophthalmopathy Market Industry is expected to grow from 1.67(USD Billion) in 2023 to 2.5 (USD Billion) by 2032. The Graves Ophthalmopathy Market CAGR (growth rate) is expected to be around 4.56% during the forecast period (2024 - 2032).
Key Graves Ophthalmopathy Market Trends Highlighted
The Graves Ophthalmopathy Market is supposed to get increasing sales owing to rising occurrence of Graves’ disease. Several key factors can be identified as active drivers of market growth, such as the deepening of patients’ knowledge about the disease, improvement of diagnostic methods, and better availability of specialized health services. In particular, novel concepts of immunotherapy and gene therapy offer new possibilities. Newest trends include increasing attention to the development of patient-centered, personalized medicines. In addition, there is an increase in telemedicine services for providing follow-up and care, especially in low-access areas.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Graves Ophthalmopathy Market Drivers
Increasing Prevalence of Thyroid Eye Disease
The major driving factors of the growth of the Graves ophthalmopathy market comprise the increasing prevalence of thyroid eye disease. According to the American Thyroid Association, Graves’ disease affects around 1 in 200 individuals in the US. Furthermore, around 30% of individuals with this condition develop Graves ophthalmopathy. The rising incidence of thyroid eye disease is due to several factors, such as the advent of advanced diagnostic methods, growing knowledge about the condition, and changes in lifestyle.Overall, as the number of individuals with Graves ophthalmopathy continues to grow, there will also be an increase in the demand for viable solutions, which will drive the growth of this market.
Technological Advancements in Treatment Options
Technological advances with regards to treatment procedures to a significant extent, the Graves ophthalmopathy market is also being encouraged by technological advances with regards to treatment options. Indeed, over the past few years, several significant advances were made in the development of new, and more effective treatments for Graves ophthalmopathy. Both targeted therapies and biologics as well as surgical techniques made it possible to achieve significant improvements as far as this health-related issue is concerned.For instance, biologics, including teprotumumab, have already shown that they can reduce the severity of Graves ophthalmopathy and improve patient outcomes. It is expected that the Graves ophthalmopathy market will experience further growth due to the emergence of new treatment options as they continue to be developed.
Growing Awareness and Patient Advocacy
The awareness of Graves ophthalmopathy and the increasing advocacy for patients are also driving the growth of the Graves ophthalmopathy market. Patient advocacy groups and organizations have been instrumental in the awareness creation process and in their advocacy for better access to care. They have worked together to educate patients and interested parties on the condition. Furthermore, the advocacy groups have helped in ensuring that there is adequate access to care for patients.Otherwise, patients will demand care and support for the condition, eventually leading to the growth of the Graves ophthalmopathy market.
Graves Ophthalmopathy Market Segment Insights
Graves Ophthalmopathy Market Treatment Type Insights
The Treatment Type segment of the Graves Ophthalmopathy Market is divided into Medical Therapy, Radiotherapy, and Surgery. Medical Therapy is the leading segment because medications, such as corticosteroids, immunosuppressive drugs, and biologics, used in curbing inflammation and suppressing the immune system are effective. Radiotherapy is another popular treatment. The treatment method utilizes radiation in reducing inflammation and shrinking the enlarged muscle. Finally, Surgery is a method of the last resort. Orbital decompression relieves pressure on the optic nerve by providing more space for the eye.The Graves Ophthalmopathy Market is worth USD 1.89 billion in 2024. It is estimated to expand at a CAGR of 4.8% from 2023 to 2032. The major drivers to this growth are the increasing prevalence of Graves’ disease, the ever-increasing health care expenditure and advancements in treatment.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Graves Ophthalmopathy Market Disease Severity Insights
The Graves Ophthalmopathy Market is segmented by disease severity into mild, moderate, and severe. The moderate segment is expected to hold the largest market share in 2023, accounting for around 45% of the Graves Ophthalmopathy Market revenue. The severe segment is expected to reach the highest CAGR of 5.2% during the forecast period. The mild segment is characterized by symptoms such as eyelid retraction, proptosis, and mild inflammation. The moderate segment includes patients with more severe symptoms, such as diplopia, corneal exposure, and optic nerve involvement.The severe segment includes patients with the most severe symptoms, such as blindness and disfigurement. The market growth for the moderate and severe segments is attributed to the increasing prevalence of Graves' disease, which is the underlying cause of Graves' ophthalmopathy. The rising awareness of the condition and the availability of new treatment options are also contributing to market growth.
Graves Ophthalmopathy Market Patients' Population Insights
The Graves Ophthalmopathy Market segmentation by Patients' Population into 'Newly Diagnosed', 'Relapsed/Refractory', and 'Resistant' provides valuable insights into the characteristics and dynamics of each patient group. In 2023, the 'Newly Diagnosed' segment accounted for a significant share of the Graves Ophthalmopathy Market revenue, driven by the increasing incidence of Graves' disease and the need for early diagnosis and treatment. This segment is expected to continue to grow steadily in the coming years due to the rising awareness of Graves' disease and the availability of advanced diagnostic techniques.The 'Relapsed/Refractory' segment represents patients who have experienced a relapse or have not responded to initial treatment. This segment is characterized by more severe symptoms and requires specialized treatment approaches. The increasing prevalence of relapsed/refractory Graves Ophthalmopathy is expected to drive the growth of this segment in the coming years. The 'Resistant' segment includes patients who do not respond to conventional treatment options and require aggressive therapies. This segment is relatively small but is expected to grow as the understanding of Graves Ophthalmopathy and its treatment modalities improves.
Graves Ophthalmopathy Market Regional Insights
The regional segmentation of the Graves Ophthalmopathy market offers insights into the market's geographic distribution and its performance across different regions. North America is expected to hold the largest market share in 2023, with a significant contribution from the United States. Europe is projected to follow North America, driven by the presence of a large patient population and well-established healthcare systems. The Asia Pacific region is anticipated to exhibit the highest growth rate during the forecast period, owing to rising awareness about the condition and increasing healthcare expenditure.South America and the Middle East and Africa are expected to account for a smaller share of the market but are projected to grow steadily over the forecast period. Key factors driving regional market growth include the prevalence of Graves' disease, healthcare infrastructure, government initiatives, and the availability of treatment options.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Graves Ophthalmopathy Market Key Players and Competitive Insights
Major players in Graves Ophthalmopathy Market are constantly striving to gain a competitive edge by investing in research and development, expanding their product portfolio, and forming strategic partnerships. Leading Graves Ophthalmopathy Market players are focusing on developing innovative treatments and therapies to cater to the evolving needs of patients. The Graves Ophthalmopathy Market industry is witnessing the emergence of novel therapeutic approaches, such as gene therapy and cell-based therapies, which hold promise for improving patient outcomes. Furthermore, key players are actively involved in clinical trials and collaborations to evaluate the efficacy and safety of new treatment modalities.
The competitive landscape is characterized by a mix of established pharmaceutical companies and emerging biotechnology firms, each bringing their unique strengths and expertise to the market.A leading player in the Graves Ophthalmopathy Market is Teva Pharmaceutical Industries Ltd. The company has a strong presence in the market with a broad portfolio of ophthalmic products, including treatments for Graves ophthalmopathy. Teva is committed to advancing research and development to bring innovative therapies to patients. It has a robust pipeline of potential treatments for Graves ophthalmopathy, including novel formulations and targeted therapies. The company's global reach and established distribution channels provide it with a competitive advantage in the market.A notable competitor in the Graves Ophthalmopathy Market is Novartis AG. The company has a strong focus on ophthalmology and is dedicated to developing and commercializing innovative treatments for eye diseases. Novartis has a portfolio of products for Graves ophthalmopathy, including immunomodulatory therapies and surgical devices. The company's research and development efforts are centered on advancing the understanding of Graves ophthalmopathy and developing new treatments to improve patient outcomes. Novartis's global presence and strong brand reputation make it a formidable competitor in the market.
Key Companies in the Graves Ophthalmopathy Market Include
Graves Ophthalmopathy Market Industry Developments
The Graves Ophthalmopathy Market is poised to reach a valuation of USD 2.5 billion by 2032, exhibiting a CAGR of 4.56% during the forecast period of 2024-2032. The increasing prevalence of Graves' disease, coupled with growing awareness of the condition, is driving market expansion. Recent advancements in treatment modalities, such as the introduction of targeted therapies and surgical techniques, are expected to further fuel market growth. Key players in the market are actively involved in research and development initiatives to enhance treatment outcomes and expand their product portfolios. Strategic collaborations and partnerships are also on the rise, aiming to combine expertise and resources to address unmet medical needs.
Graves Ophthalmopathy Market Segmentation Insights
Graves Ophthalmopathy Market Treatment Type Outlook
Graves Ophthalmopathy Market Disease Severity Outlook
Graves Ophthalmopathy Market Patients' Population Outlook
Graves Ophthalmopathy Market Regional Outlook
| Report Attribute/Metric | Details |
| Market Size 2022 | 1.6(USD Billion) |
| Market Size 2023 | 1.67(USD Billion) |
| Market Size 2032 | 2.5(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 4.56% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2023 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Johnson Johnson, Gilead Sciences, F. HoffmannLa Roche, Amgen, Teva Pharmaceutical Industries, Merck Co, Pfizer, AstraZeneca, BristolMyers Squibb, Novartis, GlaxoSmithKline, Bayer AG, Sanofi, Eli Lilly and Company, AbbVie |
| Segments Covered | Treatment Type, Disease Severity, Patients' Population, Regional |
| Key Market Opportunities | Growing prevalence of thyroid disorders Advancements in diagnosis and treatment Rising awareness about GO Increasing government initiatives Expanding research and development |
| Key Market Dynamics | Increasing Prevalence Demand for Specialized Drugs Technological Advancements Growing Awareness Government Support |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Graves Ophthalmopathy market is expected to reach USD 2.5 billion by 2032, growing at a CAGR of 4.56% from 2024 to 2032.
North America is expected to dominate the Graves Ophthalmopathy market throughout the forecast period.
The rising prevalence of Graves' disease, increasing awareness about Graves Ophthalmopathy, and technological advancements in treatment are key factors driving the growth of the Graves Ophthalmopathy market.
The major applications of Graves Ophthalmopathy treatment include medical therapy, orbital decompression surgery, and eyelid surgery.
Major players in the Graves Ophthalmopathy market include Allergan, Santen Pharmaceutical, Novartis, and Pfizer.
The Graves Ophthalmopathy market is expected to grow at a CAGR of 4.56% from 2024 to 2032.
Asia Pacific is expected to have the highest growth rate in the Graves Ophthalmopathy market during the forecast period.
Lack of awareness about Graves Ophthalmopathy and limited access to treatment options pose challenges to the growth of the Graves Ophthalmopathy market.
Growing demand for minimally invasive treatments and increasing research and development activities present opportunities for growth in the Graves Ophthalmopathy market.
Rising adoption of personalized medicine, advancements in imaging techniques, and increasing focus on early diagnosis are key trends in the Graves Ophthalmopathy market.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Assistant Manager He holds an experience of about 7+ years in market research and business consulting, working under the spectrum of life sciences and healthcare domains. rahul conceptualizes and implements a scalable business strategy and provides strategic leadership to the clients. his expertise lies in market estimation, competitive intelligence, pipeline analysis, customer assessment, etc. in addition to the above, his other responsibility includes strategic tracking of high growth markets & advising clients on the potential areas of focus they could direct their business initiatives
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
